Full Press Release Details
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI study published in peer-reviewed Oral Oncology supports Multikine's biomarker strategy and potential overall survival benefit.
CVM Positive Sentiment
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
Key Takeaway: A recent study published in the peer-reviewed journal Oral Oncology highlights the efficacy of CEL-SCI's Multikine in supporting its biomarker strategy. The findings suggest a potential overall survival benefit for patients, particularly ahead of the upcoming confirmatory registration study for head and neck cancer.
Market Sentiment Analysis
POSITIVE FACTORS
- Study supports Multikine's biomarker strategy.
- Potential overall survival benefit highlighted.
- Published in a peer-reviewed journal.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~0 mo
High dilution risk
Lead asset
LI
Phase 3 · Squamous Cell Carcinoma of the Oral Cavity
Frequently Asked Questions
What does the CEL-SCI study support?
The study supports Multikine's biomarker strategy.
Where was the CEL-SCI study published?
It was published in the peer-reviewed journal Oral Oncology.
What potential benefit does Multikine suggest?
The study suggests a potential overall survival benefit.
What is the focus of the upcoming study?
The upcoming study focuses on head and neck cancer.